In DLBCL, selective OSS_128167-mediated SIRT6 blockade inhibited PI3K/Akt/mTOR signaling and produced similar anti-lymphoma effects compared to SIRT6 knockdown in DLBCL cells. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.